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Abstract
Purpose To assess the impact of maintenance therapy and the additional impact of dexamethasone treatment on cancer-related
fatigue and sleep-wake rhythms in pediatric acute lymphoblastic leukemia (ALL) patients and to determine the association
between these outcomes.
Methods A national cohort of pediatric ALL patients (≥ 2 years) was included (± 1 year post-diagnosis). Patients receiving
dexamethasone were assessed twice (assessment with and without dexamethasone). Actigraphy assessments were used to
calculate sleep-wake outcomes with nonparametric methods. Cancer-related fatigue was assessed with the PedsQL
Multidimensional Fatigue Scale. Sleep-wake rhythms and cancer-related fatigue were compared between patients participating
in the assessment without dexamethasone and healthy children (linear regression) and between assessments with and without
dexamethasone (mixed models). Using linear regression, associations between sleep-wake outcomes and cancer-related fatigue
were determined during assessments with and without dexamethasone.
Results Responses were collected for 125 patients (113 assessments with and 81 without dexamethasone). The sleep-wake
rhythm was less stable (p = 0.03) and less robust (p = 0.01), with lower physical activity levels (p < 0.001) and higher cancer-
related fatigue levels (p < 0.001) in ALL patients compared to healthy children. Physical activity was lower (p = 0.001) and
cancer-related fatigue more severe (p ≤ 0.001) during assessments with dexamethasone compared to without dexamethasone.
Sleep-wake outcomes were significantly associated with cancer-related fatigue during periods without dexamethasone, but not
during periods with dexamethasone.
Conclusion Sleep-wake rhythms are disturbed, physical activity levels lower, and cancer-related fatigue levels higher during
maintenance therapy. Interventions aimed to enhance sleep-wake rhythms during maintenance therapy could improve cancer-
related fatigue. Families should be supported in coping with the additional burden of dexamethasone treatment to improve well-
being of ALL patients.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
type of pediatric cancer, and treatment is long and intensive.
After a first, intensive induction phase aimed to achieve com-
plete remission, the vast majority of patients receive mainte-
nance therapy until 2 to 3 years after initial diagnosis to pre-
vent relapse. Maintenance is a relative stable phase in which
most patients resume their normal daily activities. However,
maintenance therapy still consists of frequent intravenous and/
or oral chemotherapy administrations and treatment-related
toxicities and hospital admissions are common [1].
Moreover, main tenance therapy includes cyc l ic
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glucocorticoids treatment in the majority of patients.
Glucocorticoids, and particularly dexamethasone, are known
for their neurobehavioral side effects, among which are sleep
disturbances [2–5].
Pediatric patients with ALL during maintenance are vul-
nerable to disturbed sleep and sleep-wake rhythms for several
reasons. Several physical (treatment-related toxicities such as
pain or fever/infectious diseases), psychosocial (for example
anxiety) and social stressors (for example impaired school
attendance and changed family routines) during maintenance
treatment might hamper sleep quality and quantity, as well as
sleep hygiene. Changed parenting strategies, such as more lax
parenting, pampering, and bribing, have been described in
childhood oncology populations and could impede sleep hy-
giene [6–8]. The additional effect of dexamethasone treatment
during maintenance treatment may also cause sleep and sleep-
wake rhythm disturbances. The underlying mechanisms of
sleep problems and sleep-wake rhythm disturbances during
dexamethasone treatment are not yet fully understood. The
unbalanced glucocorticoid receptor (GR) and mineralocorti-
coid receptor (MR) occupation in the brain has been described
previously as a potential cause of dexamethasone-induced
neurobehavioral side effects [2, 9, 10]. The hypothalamus-
pituitary-adrenal axis (HPA axis) is important for sleep
through the synthesis of cortisol [11, 12]. Previous studies
described an association between cortisol and sleep and
sleep-wake rhythm outcomes [12–14]. In the brain, cortisol
binds both the MR and the GR [11]. Cortisol binding to the
MR and GR stimulates slow wave sleep and inhibits rapid eye
movement sleep [11]. Compared to cortisol, dexamethasone
has a higher affinity for the GR, whereas it does not bind the
MR in the brain [2, 10]. Through a negative feedback loop
acting on the HPA axis, dexamethasone suppresses endoge-
nous cortisol production. This leads to (over)activation of the
GR and complete endogenous ligand depletion or lower oc-
cupancy of the MR in the brain [10]. Kellner et al. reported
that endogenous receptor occupancy and regulation seem to
be important for the effect of the MR on sleep [15]. Therefore,
dexamethasone-induced depletion of cortisol and the subse-
quent unbalanced receptor binding in the brain may play a role
in the etiology of sleep and sleep-wake rhythm disturbances in
patients treated with dexamethasone. Additionally, the
(behavioral) side effects of dexamethasone, such as excessive
eating, aggressive moods, and depressive symptoms, may di-
rectly interfere with appropriate sleep hygiene and thereby
impair sleep and sleep-wake rhythmicity [3, 5].
While sleep disturbances such as nighttime awakenings,
sleep anxiety, bedtime resistance, and parasomnias have pre-
viously been described, evidence on sleep-wake rhythms dur-
ing pediatric ALL maintenance therapy is scarce [16–18].
Only a single study in pediatric ALL patients described im-
paired sleep-wake rhythmicity after dexamethasone initiation
[19]. However, since sleep-wake rhythms were not compared
to healthy children in this previous study, it is not yet known
whether sleep-wake rhythms are actually disturbed.
Cancer-related fatigue is one of the most common side
effects of anticancer treatments, and increased severity has
been described during dexamethasone treatment [20–22].
Cancer-related fatigue is a disabling symptom that often con-
tinues after cessation of treatment [23]. It impairs school func-
tioning and reduces the ability to participate in social roles and
activities [24, 25]. It is a multidimensional problem, but the
etiology is not yet fully understood [20]. A biopsychosocial
model including demographic, biological, medical, function-
al, and behavioral factors contributing to cancer-related fa-
tigue seems likely [20]. A relationship between sleep-wake
rhythm disturbances and cancer-related fatigue has previously
been described in pediatric oncology populations [19, 26].
This suggests that the sleep-wake rhythm plays a role in the
etiology of cancer-related fatigue.
Given the high burden of maintenance treatment and its
potential implications for the sleep-wake rhythm and cancer-
related fatigue, it is important to better understand these rela-
tionships in pediatric ALL patients. This might provide oppor-
tunities for interventions to increase well-being of ALL
patients.
Therefore, this study aimed to (1) compare sleep-wake
rhythms and cancer-related fatigue of pediatric ALL patients
during maintenance therapy to healthy children; (2) determine
the additional effect of dexamethasone treatment on these out-
comes; and (3) assess the association between sleep-wake
outcomes and cancer-related fatigue.
Methods
The results described here are part of the SLAAP [SLEEP]
study (SLeep in children with Acute lymphoblastic leukemia
And their Parents), an observational, longitudinal, multicenter
study on sleep, sleep-wake rhythms, quality of life and cancer-
related fatigue in pediatric ALL patients and functioning of
their parents. Results on sleep-wake rhythms and cancer-
related fatigue measured at 1 year post-diagnosis are reported
here.
Patients were identified through the Dutch Childhood
Oncology Group (DCOG) registry that includes all pediatric
patients with a diagnosis of cancer in the Netherlands. Patients
were eligible if they were (1) diagnosed with primary ALL
and treated according to the national first-line DCOG treat-
ment protocol ALL-11, open to patients aged 1 to 19 years,
and (2) ≥ 2 years of age at assessment. Furthermore, parents
and patients needed to master Dutch sufficiently to complete
the questionnaires. Patients were recruited in the following
Dutch pediatric oncology centers: Emma Children’s
Hospital/Academic Medical Center and VU University
Medical Center Amsterdam, Wilhelmina’s Children’s
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Hospital/University Medical Center Utrecht, Princess
Máxima Center for pediatric oncology Utrecht, Sophia
Children’s Hospital/Erasmus Medical Center Rotterdam,
Beatrix Children’s Hospital/University Medical Center
Groningen, Amalia Children’s Hospital/Radboud University
Medical Center Nijmegen. Parents and patients (≥ 12 years)
provided informed consent for participation. The Institutional
Review Board of the Erasmus Medical Center approved this
study.
The study assessments were planned around 1 year after
diagnosis, during maintenance therapy. During this phase,
ALL treatment intensity depends on risk group stratification.
Patients were stratified to the following risk groups, with in-
creasing treatment intensity, based on response to treatment
and cytogenetics: standard risk (SR), medium risk (MR) and
high risk (HR). SR maintenance therapy consisted of daily
oral mercaptupurine and weekly oral methotrexate. During
the study assessment, maintenance therapy for MR group pa-
tients consisted of continuous oral mercaptupurine, weekly
intravenous methotrexate administrations, 3-weekly vincris-
tine administrations, and cyclic oral dexamethasone treatment
(21-day cycles: 5 days with dexamethasone alternated with
16 days without dexamethasone). In addition, MR patients
received intrathecal chemotherapy around once per 4 months.
Assessments were planned during a week without intrathecal
chemotherapy. Only one HR patient completed the study and
was excluded from the analyses described here because of the
higher treatment intensity for HR patients compared to SR and
MR patients.
A single assessment was planned for SR patients. Two
assessments were planned forMR patients: (1) during a period
with dexamethasone and (2) during a period without dexa-
methasone. Participants were instructed to start the actigraphy
assessment during the period with dexamethasone the first day
of the 5-day dexamethasone treatment and the assessment
without dexamethasone 7 day before start of a following dexa-
methasone treatment cycle. Participants were instructed to
complete the questionnaires (regarding functioning during
the assessment week) at a self-chosen day during that week.
To reduce the burden to the families, assessments were pref-
erably planned with at least one 21-day treatment cycle in
between. Whether the first assessment was during a period
with or without dexamethasone was based on patient/parent
preference. The assessments, including questionnaires and
actigraphic recordings, took place at home.
Measures
Sociodemographic and medical information
Parents filled out a survey to collect the following
sociodemographic information: patient and parental age and
sex, child’s sleep medication use (yes or no), and parental
highest attained educational level. Educational level was de-
fined according to Statistics Netherlands [27] and dichoto-
mized as lower (low and middle educational level) versus
higher (high educational level). Information on time since
diagnosis and risk group stratification was collected through
the DCOG.
Actigraphy-derived sleep-wake rhythm
Actigraphy assessments were used to calculate sleep-wake
rhythm outcomes. An actigraph (ActiGraph wGT3X-BT,
Pensacola, FL, USA) is a nonintrusive device that measures
the occurrence and intensity of limb movements. Patients
were instructed to wear the actigraph on their wrist for 24 h
for 7 days. Actigraphy has been validated against
polysomnography and has proven to be an adequate method
to measure sleep-wake patterns in infants, children, and ado-
lescents [28–30]. Participants were instructed to record sleep-
wake schedule information in a sleep log to facilitate correct
interpretation of the actigraphy data. Invalid data, defined as
probable non-wear time ≥ 3 consecutive hours, was identified
[31]. A 24-h period starting at the onset of this non-wear time
was then removed from further analysis [31]. Sleep-wake out-
comes were calculated if valid data was available for at least
72 h [32].
There are different approaches to quantify sleep-wake
actigraphic recordings. Two commonly used methods are the
cosinor analysis and the nonparametric method. Cosinor anal-
ysis is parametric and presumes that the activity level variation
over the day is best described with a 12:12 h symmetrical
sinusoidal. However, the sleep-wake rhythm, particularly in
children, is far from symmetrical and sinusoidal. To better
accommodate the non-sinusoidal, asymmetric activity pattern
of everyday life, nonparametric methods have been proposed,
that do not make assumptions about the distribution of the
rhythm. Accordingly, the nonparametric method seems to de-
scribe the sleep-wake pattern more accurately than cosinor
analysis [32, 33]. Nonparametric methods were used to obtain
the following sleep-wake rhythm variables (definitions are
provided in Table 1): interdaily stability (IS), intradaily vari-
ability (IV), M5 counts, M10 counts, and relative amplitude
(RA) [33].
For comparison, sleep-wake rhythm variables were also
obtained in healthy children, aged 2–18 years with the same
type of actigraph [34]. Recruitment took place through snow-
ball sampling and word of mouth referrals within the profes-
sional and social network of the research team. Children were
not eligible if they visited a health care provider for sleep
disturbances in the preceding 3 months, used any type of sleep
medication (including melatonin), or had a medical condition
that could potentially affect sleep or the circadian rhythm (ep-
ilepsy, blindness, exacerbation of asthma or severe eczema).
Additionally, children were excluded if they or their parents
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were insufficiently fluent in Dutch. Actigraphy data was col-
lected in the same manner as in patients with ALL. Valid
actigraphy data was available for 85 healthy children (median
age 8.5 years [interquartile range 5.5–15.3], 50.6% boys,
highest parental educational level: 34.1% lower educational
level and 65.9% higher educational level).
Cancer-related fatigue
The Dutch parent -proxy vers ion of the PedsQL
Multidimensional Fatigue Scale (PedsQL MFS) was used to
assess cancer-related fatigue [35, 36]. This 18-item question-
naire allows for an overall fatigue score and three subscale
scores: general fatigue, sleep-rest fatigue and cognitive fa-
tigue. The occurrence of problems is assessed over the past
week on a 5-point Likert scale. Items are rescored to a 0–100
scale. A higher score indicates less cancer-related fatigue. The
subscale scores were used in this study. Scores in healthy
Dutch children have previously been collected by Gordijn
et al. [35]. The internal consistency of the subscales was ade-
quate (Cronbach’s alpha > 0.70) in the population of healthy
children as well as in the study population. The questionnaire
was completed paper-pencil or through a secured online web
portal depending on parent preference.
Statistical analysis
Data from the assessments in MR patients during the period
without dexamethasone and in SR patients were analyzed as
one group to represent the ALL population during mainte-
nance therapy that participated in the assessment without
dexamethasone. Additional analyses showed that there were
no statistically significant differences in sleep-wake rhythms
and cancer-related fatigue between these patients
(Supplemental Table S1). Data from the assessment with
dexamethasone in MR patients were analyzed to reflect the
additional burden of dexamethasone treatment inMR patients.
Descriptive statistics of socio-demographics and medical
factors are presented for patients that participated in the as-
sessment without dexamethasone (including SR and MR
patients during periods without dexamethasone) and MR pa-
tients that participated in the assessment with dexamethasone
separately.
Sleep-wake outcomes and cancer-related fatigue scores
were presented for both patient groups and healthy children.
Outcomes of assessments without dexamethasone were com-
pared to healthy children using linear regression models.
Regression models were adjusted for patient age, sex, sleep
medication use, and parental educational level as differences
in these outcomes between patients with ALL and healthy
children could affect sleep-wake rhythm outcomes and
cancer-related fatigue. In addition, the regression models for
cancer-related fatigue were adjusted for parental sex, since
parent-reports may differ between fathers and mothers.
Additionally, sleep-wake outcomes and cancer-related fa-
tigue scores were compared between patients that participated
in the assessment without dexamethasone and MR patients
that participated in the assessment with dexamethasone.
Mixed model analyses were used to correct for the dependen-
cy ofMR patients that participated in both the assessment with
and without dexamethasone. Analyses were adjusted for pa-
tient age, sex, sleep medication use, time since diagnosis, and
parental educational level.
Associations between sleep-wake outcomes and cancer-
related fatigue were evaluated with linear regression models
for assessments with and without dexamethasone separately.
Regressions models were adjusted for patient age, sex, sleep
medication use, risk group stratification, time since diagnosis,
and parental educational level.
Results
Details regarding the patient enrollment are described in
Fig. 1. Informed consent was provided for 151 patients, of
whom 125 completed at least one of the study assessments
described here. The assessment without dexamethasone was
completed by 113 patients, including 30 SR and 83 MR pa-
tients. They completed 73 valid sleep-wake rhythm assess-
ments and 111 parent-reports on cancer-related fatigue. The
Table 1 Definitions of the sleep-wake rhythm variables
Variable Range Definition
Interdaily stability (IS) 0–1 An estimate of the stability of the rhythm, and describes the synchronization of the rhythm,
wherein 1 signifies a perfect synchronization to the dark-light cycle
Intradaily variability (IV) 0–2 An estimate of the 24-h rest-activity rhythm and reflects the fragmentation of the rhythm,
a higher IV indicates a more fragmented rhythm
L5 counts 0–∞ Activity counts (physical activity) during the least active 5 h of the day.
M10 counts 0–∞ Activity counts (physical activity) during the most active 10 h of the day.
Relative amplitude (RA) 0–1 Ratio of the difference and the sum of M10 and L5 counts. A higher RA indicates a bigger
difference between the least and most active period during the day, hence a better sleep-wake rhythm.
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assessment with dexamethasone was completed by 81 out of
90 eligible MR patients, who completed 51 valid sleep-wake
rhythm assessments and 80 cancer-related fatigue parent-
reports.
Patient and parental socio-demographics and patient med-
ical factors were comparable for patients that participated in
the assessments without dexamethasone and for MR patients
that participated in the assessment with dexamethasone
(Table 2).
Sleep-wake outcomes
Descriptive statistics of sleep-wake outcomes of ALL
patients and healthy children are shown in Table 3. IS
(B = − 0.04, p = 0.030), M10 counts (B = − 412.23,
p < 0.001), and RA (B = − 0.02, p = 0.012) were signifi-
cantly lower in ALL patients participating in the assess-
ment without dexamethasone compared to healthy chil-
dren, reflecting a less stable and less robust rhythm, and
lower physical activity in ALL patients (Supplemental
Table S2). IV and L5 counts were not significantly dif-
ferent from healthy children. During assessments with-
out dexamethasone, M10 counts were significantly
higher (B = 254.94, p = 0.001) compared to assessment
with dexamethasone in MR patients (Supplemental
Table S3). Other sleep-wake outcomes were not differ-
e n t b e twe e n a s s e s smen t s w i t h a n d w i t h o u t
dexamethasone.
Cancer-related fatigue
Descriptive statistics of cancer-related fatigue scores of pa-
tients and healthy children are shown in Table 3. General
(B = − 17.52, p < 0.001) and sleep-rest (B = − 12.11,
p < 0.001) fatigue scores were significantly lower (reflecting
higher levels of cancer-related fatigue) in patients participating
in the assessment without dexamethasone compared to
healthy children (Supplemental Table S2). Cancer-related fa-
tigue scores were significantly higher, indicating lower levels
of cancer-related fatigue, during assessments without dexa-
methasone compared to assessments with dexamethasone
(general (B = 10.50, p = 0.001), sleep-rest (B = 10.63,
p < 0.001), and cognitive fatigue (B = 9.63, p = 0.001))
(Supplemental Table S3).
Association between sleep-wake outcomes
and cancer-related fatigue
During assessments without dexamethasone, higher M10
counts (higher physical activity) and higher RA (more robust
rhythm) were significantly associated with lower levels of
cancer-related fatigue (all subscales). Lower IV, indicating a
less fragmented rhythm, was significantly associated with less
sleep-rest fatigue (Table 4). Higher L5 counts, reflecting
higher activity during the 5 least active hours of the day, were
associated with more sleep-rest fatigue (Table 4). Associations
Eligible n=276
Approached n=225
Not invited (n=51):
Physician decision/paent burden n=7
Logiscal issues n=18
Severe course of the disease/complicaons/deceased
before introducon of the study n=11
Declined parcipaon in any study n=8
Others/unknown n=7 
Informed consent 
n=151
No informed consent (n=74):
Burden of the study n=35
Complicaons/treatment intensity n=4
Parcipaon in other studies n=3
Parental factors n=4
Others n=5
Unknown n=23
Completed at least
one of the study
elements
n=125 
No completed measurements (n=26):
Withdrawn informed consent n=19
Missing data/invalid data n=7 
Completed at least one of the
study elements during the period
without dexamethasone
n=113/125 
Completed at least one of the
study elements during the period
with dexamethasone
n=81/90 
Valid sleep-wake rhythm 
assessments: 73
- Standard risk paents: 19
- Medium risk paents: 54
Cancer-related fague: 111
- Standard risk paents: 30
- Medium risk paents: 81
Valid sleep-wake rhythm 
assesssments: 51
Cancer-related fague: 80
Fig. 1 Patient enrollment
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were not statistically significant for MR patients during pe-
riods with dexamethasone.
Discussion
During maintenance therapy, pediatric patients with ALL
demonstrated disturbed sleep-wake rhythms, lower physical
activity levels, and increased levels of cancer-related fatigue
compared to healthy children. During dexamethasone periods,
patients showed even lower physical activity and more severe
cancer-related fatigue.
The reduced stability and robustness of the sleep-wake
rhythm in ALL patients duringmaintenance therapymay have
several reasons. First, to align the circadian sleep-wake cycle
to the environmental 24-h light-dark cycle it needs to be syn-
chronized by external cues, such as light, scheduled sleep,
physical activity, and meals [37–40]. Several factors during
ALL maintenance therapy can alter these external cues and
thereby hamper appropriate synchronization of the sleep-
wake rhythm. Treatment-related toxicities, psychological
stressors, and environmental noises during hospitalization
may, for example, influence light exposure, physical activity,
social activities, and school attendance. Second, more lenient
parenting that has been described in ALL patients may impair
limit setting regarding sleep hygiene, subsequently resulting
in sleep-wake rhythm disturbances [6, 7].
Daytime napping and night awakenings have been de-
scribed in pediatric patients with ALL, which may reflect in
fragmentation of the sleep-wake rhythm. Considering the
physical and psychosocial stressors related to ALL treatment,
increased fragmentation of the rhythm was expected [16, 22,
41]. However, fragmentation of the sleep-wake rhythm was
not increased in the current study. This is probably the result of
the low overall physical activity levels in our sample.
Moreover, consistent with our results, intradaily variability
was within normal limits in hospitalized children with central
nervous system cancer [26].
More disturbed sleep-wake rhythms were expected during
dexamethasone treatment as has been described previously
[19]. However, except for lower physical activity levels,
sleep-wake rhythms were not different between assessments
with and without dexamethasone. We hypothesized that the
unbalanced glucocorticoid receptor occupancy plays a role in
the etiology of sleep-wake rhythm disturbances during dexa-
methasone treatment [2, 9–11]. However, based on the short
half-life time (1.27 h) of oral dexamethasone, the receptor
occupancy would expected to be restored during the intervals
without dexamethasone [42]. The biological effect of dexa-
methasone might still precipitate sleep-wake rhythm distur-
bances. Perpetuating factors may subsequently cause longer
term sleep-wake rhythm disturbances. For example, the emo-
tional and behavioral side-effects of dexamethasone may in-
duce structural behavioral changes. These behavioral changes
Table 2 Baseline characteristics for patients with ALL during periods with and without dexamethasone
Patients participating in the assessment
without dexamethasonea (n = 113)
Patients participating in the assessment
with dexamethasone (n = 81)
Patient- and treatment-related factors
Patient age at diagnosis in years, median [IQR] 4.8 [3.0–8.7] 5.0 [3.0–9.6]
Female patient sex, N (%) 50 (44.2) 33 (40.6)
Risk group stratification, N (%)
Standard risk group 30 –
Medium risk group 83 81 (100)
Time since diagnosis in months, median [IQR] 13.5 [12.7–14.0] 12.8 [12.4–13.5]
Use of sleep medication, N (%) 14 (12.4) 9 (11.1)
Parental- and family factors
Parental age in years, mean ± SD 38.9 (6.1) 39.5 (6.9)
Female parental sex, N (%) 91 (80.5) 63 (77.8)
Educational level, N (%)b
Low 3 (2.7) 2 (2.5)
Middle 29.0 (25.7) 20 (24.7)
High 77 (68.1) 55 (67.9)
Unknown 4 (3.5) 4 (4.9)
N number, SD standard deviation, IQR interquartile range, ALL acute lymphoblastic leukemia
a Include both standard and medium risk group patients
b Low educational level = no education, primary school, lower secondary education; middle educational level = upper secondary education, pre-univer-
sity education, intermediate vocational education; high educational level = higher vocational education, university
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might in turn result in adapted parenting strategies that have
previously been described and changed family routines [6, 7].
The behavioral changes and changed family structures do
probably not resolve in the short intervals between consecu-
tive dexamethasone cycles and hamper reversibility of sleep-
wake rhythm disturbances in-between dexamethasone cycles.
Higher levels of cancer-related fatigue were reported for
patients participating in assessments without dexamethasone
compared to healthy children, with the exception of cognitive
fatigue. The absence of cognitive fatigue is in line with a
previous study in adolescent cancer patients and is probably
the result of lower cognitive demands and expectations during
ALL treatment [43]. Furthermore, we confirmed the previous-
ly described increased cancer-related fatigue levels during pe-
riods with dexamethasone [22]. In patients participating in the
assessments without dexamethasone, sleep-wake rhythm dis-
turbances were significantly associated with more severe
cancer-related fatigue. The absence of this relationship during
assessments with dexamethasone indicates that the additional
cancer-related fatigue during periods with dexamethasone is
independent of the sleep-wake rhythm. The additional cancer-
related fatigue during assessments with dexamethasone may
have several reasons. First, the group of patients that partici-
pated in the assessment without dexamethasone also includes
SR patients, whereas patients participating in the assessment
with dexamethasone wereMR patients only. The higher levels
of cancer-related fatigue during periods with dexamethasone
may reflect the higher treatment burden for MR patients
(weekly hospital visits, intravenous methotrexate, and 3-
weekly vincristine administration). However, no differences
were found between MR patients during periods without
dexamethasone and SR patients, but the small number of SR
patients could have limited the power to find a significant
difference. Second, the depressive symptoms and the associ-
ated lethargy described during dexamethasone may be per-
ceived as cancer-related fatigue [5]. Third, parental demands
are higher during dexamethasone given the many neurobehav-
ioral side-effects which may result in a higher parent per-
ceived burden and overreporting of symptoms.
Given the impact of maintenance treatment on sleep-wake
rhythms and cancer-related fatigue, clinicians should pay at-
tention to these outcomes and families should be supported in
coping with this in general, and with the additional burden of
dexamethasone treatment in particular. Implementation of in-
terventions to restore healthy sleep-wake rhythms could pro-
vide opportunities to improve cancer-related fatigue during
maintenance therapy. In a previous study in pediatric patients
with ALL, hydrocortisone addition to dexamethasone treat-
ment, to achieve a more balanced receptor occupancy, reduced
neurobehavioral side effects in patients with severe behavioral
and sleep problems [2]. A validation study in patients with
severe behavioral and sleep problems is currently ongoing.
Table 3 Sleep-wake rhythm variables and cancer-related fatigue in patients with ALL and in healthy children
Patients participating in the assessment
without dexamethasonea (n = 73)
Patients participating in the assessment
with dexamethasone (n = 51)
Healthy children (n = 85)
Sleep-wake rhythm variables Mean ± SD and median [IQR] Mean ± SD and median [IQR] Mean ± SD and median [IQR]
Interdaily stability 0.61 ± 0.11 0.59 ± 0.12 0.62 ± 0.13
0.64 [0.53–0.69] 0.60 [0.51–0.68] 0.63 [0.55–0.71]
Intradaily variability 0.74 ± 0.21 0.75 ± 0.21 0.72 ± 0.20
0.70 [0.57–0.85] 0.70 [0.61–0.88] 0.69 [0.58–0.83]
L5 counts 53.22 ± 25.13 57.56 ± 25.81 51.85 ± 23.95
48.92 [34.88–64.53] 53.66 [37.67–68.63] 46.32 [36.25–63.50]
M10 counts 1892.79 ± 662.09 1524.26 ± 600.23 2187.10 ± 709.33
1992.12 [1573.08–2349.36] 1428.77 [1112.88–1969.25] 2244.55 [1520.47–2658.15]
Relative amplitude 0.93 ± 0.07 0.92 ± 0.05 0.95 ± 0.03
0.94 [0.93–0.97] 0.93 [0.89–0.96] 0.96 [0.94–0.97]
Patients participating in the assessment
without dexamethasonea (n = 111)
Patients participating in the assessment
with dexamethasone (n = 80)
Healthy children (n = 497)34
Cancer-related fatigue Mean ± SD and median [IQR] Mean ± SD and median [IQR] Mean ± SD and median [IQR]
General fatigue 62.76 ± 22.11 50.13 ± 23.19 81.27 ± 14.17
62.50 [50.00–75.00] 45.83 [33.33–66.67] 83.33 [70.83–91.67]
Sleep-rest fatigue 71.51 ± 19.79 60.49 ± 17.94 83.84 ± 13.86
75.00 [58.33–87.50] 59.17 [46.88–73.96] 87.50 [75.00–95.83]
Cognitive fatigue 78.75 ± 18.99 71.04 ± 20.70 78.48 ± 17.93
75.00 [66.67–95.83] 75.00 [58.33–91.67] 79.17 [66.67–95.83]
ALL acute lymphoblastic leukemia, SD standard deviation, IQR interquartile range, N number
a Include both standard and medium risk group patients
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Based on the hypothesis that sleep-wake rhythm disturbances
during maintenance treatment are precipitated by the unbal-
anced receptor occupancy, hydrocortisone might also be an
effective intervention to prevent sleep-wake rhythm distur-
bances. Furthermore, interventions to encourage physical ac-
tivity could enhance sleep-wake rhythms and have proven to
be feasible in pediatric patients with ALL [44]. Finally, the
reduced stability and robustness of the sleep-wake rhythm
might result from impaired sleep hygiene during maintenance
therapy. Systematic monitoring of sleep and attention to sleep
hygiene during ALL treatment may provide opportunities for
early interventions to prevent sleep-wake rhythm distur-
bances. Knowledge on healthy child sleep in parents is gen-
erally poor. Educational interventions have proven to effec-
tively improve knowledge in parents of healthy children [45,
46]. Such educational interventions could potentially improve
sleep hygiene in pediatric patients with ALL and thereby en-
hance sleep-wake rhythms. Psycho-education should include
information on healthy sleep habits and address incorrect cog-
nitions on sleep. Information on physical activity should be
incorporated to encourage low intensity physical activity,
within the limits of the physical condition of the child.
Moreover, information on neurobehavioral side effects of
dexamethasone could support parents in coping with these
side effects. Additionally, providing eye mask and ear plugs
during hospitalization could reduce the environmental impact
on sleep-wake rhythms [47].
Some limitations of this study need to be mentioned. First,
not all patients participated in all study assessments. Hence,
selection bias and participation bias, for example based on
treatment-related toxicity, cannot completely be ruled out.
The study may therefore have underestimated sleep-wake
rhythm disturbances and cancer-related fatigue. Second, par-
ticipants were instructed to start the actigraphy assess-
ment during the period with dexamethasone on the first
day of dexamethasone treatment. However, it was not
registered which day of the dexamethasone cycle partic-
ipants actually started the assessment. Since sleep-wake
rhythm assessments lasted 7 days, we could have mea-
sured washout effects of dexamethasone. Third, self-
reported cancer-related fatigue was not taken into ac-
count while disagreement between parent- and self-
reports has been reported in childhood oncology [48].
Finally, since a lower socio-economic status has been
associated with less healthy sleep behaviors, the over-
representation of highly educated families in our study
may have underestimated the prevalence and severity of
disturbed sleep-wake rhythms [27, 49].
In conclusion, sleep-wake rhythms were disturbed and
cancer-related fatigue levels were increased in pediatric pa-
tients with ALL during maintenance therapy. During periods
with dexamethasone patients showed even lower physical ac-
tivity and higher levels of cancer-related fatigue. More dis-
turbed sleep-wake rhythms were associated with higher levels
of cancer-related fatigue during periods without dexametha-
sone. Interventions aimed to enhance sleep-wake rhythms and
support of families in coping with sleep-wake rhythm distur-
bances and with the additional burden of dexamethasone
Table 4 Association between sleep-wake rhythm variables (actigraphy derived) and cancer-related fatigue (PedsQLMFS scores) in patients with ALL
General fatigue B (95% CI)a Sleep-rest fatigue B (95% CI) a Cognitive fatigue B (95% CI) a
Patients participating in the assessment without dexamethasone (n = 69)
Interdaily stability (0.1 change) 4.47 (− 1.05; − 10.00) 6.85 (2.12; 11.57)** 1.30 (−3.60; 6.20)
Intradaily variability (0.1 change) − 4.87 (− 7.81; 1.93)** − 4.63 (− 7.22; − 2.03)** − 3.05 (− 5.72; − 3.81)**
L5 counts (10 counts change) − 1.83 (− 4.06; 0.41) − 2.11 (− 4.08; − 0.14)** − 0.54 (− 2.53; 1.44)
M10 counts (10 counts change) 0.22 (0.14; 0.31)* 0.22 (0.15; 0.29)* 0.14 (0.06; 0.22)**
Relative amplitude (0.1 change) 14.55 (6.96; 22.14)* 17.12 (10.97; 23.27)* 9.06 (2.08; 16.05)**
Patients participating in the assessment with dexamethasone (n = 47)
Interdaily stability (0.1 change) 3.38 (− 3.80; 10.56) 4.61 (− 0.89; 10.12) − 4.29 (− 11.30; 2.72)
Intradaily variability (0.1 change) 2.56 (− 1.26; 6.37) − 0.91 (− 3.97; 21.39) 1.34 (− 2.29; 51.56)
L5 counts (10 counts change) − 0.89 (− 3.57; 1.79) − 1.34 (− 3.41; 0.74) − 0.64 (− 3.23; 1.94)
M10 counts (10 counts change) 0.04 (− 0.11; 0.18) 0.05 (− 0.06; 0.17) − 0.01 (− 0.02; 0.01)
Relative amplitude (0.1 change) 8.60 (− 7.98; 25.18) 10.34 (− 2.45; 23.12) − 1.10 (− 17.26; 15.07)
ALL acute lymphoblastic leukemia, CI confidence interval,MFSMultidimensional Fatigue Scale, N number, L5 counts activity counts during the least
active 5 h of the day, M10 counts activity counts during the most active 10 h of the day
Significant associations are italicized; *p value < 0.05; **p value < 0.001
aAdjusted for child’s age, sex and current sleep medication use, risk group stratification, time since diagnosis and highest attained parental educational
level
b Adjusted for child’s age, sex and current sleep medication use, time since diagnosis and highest attained parental educational level
Support Care Cancer
treatment in particular could improve well-being of ALL pa-
tients and their families during maintenance therapy.
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